HK Stock Market Move | ABBIKKO-B (02256) rose by more than 11%. Recent publication of the results of the joint study ABSK061 in combination with ABSK043 for the treatment of FGFR2-positive advanced GC/GEJC in Phase II.

ABBISKO-B (02256) rose more than 11%, rising 9.08% to HK $10.21 at the time of reporting, with a trading volume of HK $23.6689 million. On the news front, on June 26, ABBISKO-B announced that its subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine) announced at the 2026 American Society of Clinical Oncology (ASCO) annual meeting that the company has presented preliminary results of its Phase II clinical study of the first-in-class oral high-selective FGFR2/3 inhibitor ABSK061 combined with the oral PD-L1 inhibitor ABSK043, with or without CAPOX (oxaliplatin combined with capecitabine) for the treatment of FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC) that they have independently developed. The study data showed that the combination of ABSK061 and ABSK043, with or without CAPOX, demonstrated good safety and positive antitumor activity in FGFR2-positive advanced GC/GEJC patients, highlighting the potential of this targeted combination immunotherapy strategy as a novel treatment option for this patient population.